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BACKGROUND: Cangrelor is an intravenous P2Y12 inhibitor approved 
to reduce periprocedural ischemic events in patients undergoing 
percutaneous coronary intervention not pretreated with a P2Y12 inhibitor.
METHODS: A total of 11 145 patients were randomized to cangrelor or 
clopidogrel in the CHAMPION PHOENIX trial (Cangrelor versus Standard 
Therapy to Achieve Optimal Management of Platelet Inhibition). We explored 
the effects of cangrelor on myocardial infarction (MI) using different 
definitions and performed sensitivity analyses on the primary end point of 
the trial.
RESULTS: A total of 462 patients (4.2%) undergoing percutaneous 
coronary intervention had an MI as defined by the second universal 
definition. The majority of these MIs (n=433, 93.7%) were type 4a. 
Treatment with cangrelor reduced the incidence of MI at 48 hours (3.8% 
versus 4.7%; odds ratio [OR], 0.80; 95% confidence interval [CI], 0.67–
0.97; P=0.02). When the Society of Coronary Angiography and Intervention 
definition of periprocedural MI was applied to potential ischemic events, 
there were fewer total MIs (n=134); however, the effects of cangrelor 
on MI remained significant (OR, 0.65; 95% CI, 0.46–0.92; P=0.01). 
Similar effects were seen in the evaluation of the effects of cangrelor on 
MIs with peak creatinine kinase-MB ≥10 times the upper limit of normal 
(OR, 0.64; 95% CI, 0.45–0.91) and those with peak creatinine kinase-
MB ≥10 times the upper limit of normal, ischemic symptoms, or ECG 
changes (OR, 0.63; 95% CI, 0.48–0.84). MIs defined by any of these 
definitions were associated with increased risk of death at 30 days. 
Treatment with cangrelor reduced the composite end point of death, MI 
(Society of Coronary Angiography and Intervention definition), ischemia-
driven revascularization, or Academic Research Consortium definite stent 
thrombosis (1.4% versus 2.1%; OR, 0.69; 95% CI, 0.51–0.92).
CONCLUSIONS: MI in patients undergoing percutaneous coronary 
intervention, regardless of definition, remains associated with increased 
risk of death in the current era. Cangrelor compared with clopidogrel 
significantly reduces MI regardless of the definition.
CLINICAL TRIAL REGISTRATION: URL: http://clinicaltrials.gov. Unique 
identifier: NCT01156571.
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cangrelor is a reversible, intravenous adenosine diphosphate receptor antagonist and has a rapid onset and offset of its antiplatelet effects. Cangre-
lor has been approved for use in patients undergoing 
percutaneous coronary intervention (PCI) not pretreated 
with a P2Y12 inhibitor on the basis of the results of the 
CHAMPION PHOENIX trial (Cangrelor versus Standard 
Therapy to Achieve Optimal Management of Platelet In-
hibition).1 The CHAMPION PHOENIX trial compared can-
grelor with clopidogrel in patients undergoing PCI and 
found that cangrelor reduced the composite end point of 
death, myocardial infarction (MI), ischemia-driven revas-
cularization, or stent thrombosis by 22%.1 The definition 
of MI used in the trial was based on the second universal 
definition of MI, and the protocol mandated the collection 
of blood samples to test for biomarkers of myonecrosis 
after the initial PCI.2 A core laboratory also reviewed all 
angiograms from the index PCI to determine whether 
there was evidence of angiographic complications dur-
ing the procedure, including intraprocedural stent throm-
bosis (IPST).3
Some have questioned whether MIs and IPST detect-
ed through these standardized efforts represent clinical-
ly meaningful events. In this analysis, we sought to de-
termine whether changes in the definition of MI or stent 
thrombosis would have affected the overall primary end 
point of the trial. Additionally, we aimed to evaluate the 
effects of cangrelor on MIs of different sizes and types. 
Finally, we sought to better understand the impact of 
the different definitions on the incidence of MI and the 
prognosis of patients who have an MI.
MethODs
study Population and Design
CHAMPION PHOENIX was a double-blind, placebo-controlled 
trial that randomized 11 145 patients who were undergoing 
PCI to either intravenous cangrelor or clopidogrel. The full 
inclusion and exclusion criteria and protocol of the trial have 
been reported previously.1,4 In brief, patients were eligible for 
the trial if they had not been treated previously with platelet 
inhibitors and were undergoing PCI for ST-segment–elevation 
MI, non–ST-segment–elevation acute coronary syndrome, or 
stable angina.
Patients were randomized to receive either cangrelor fol-
lowed by clopidogrel after the infusion of cangrelor was com-
plete or clopidogrel as soon as possible after randomization. 
Patients randomized to cangrelor received an infusion of 
cangrelor (30 μg/kg followed by an infusion of 4 μg/kg per 
minute) and placebo capsules. Cangrelor was continued for 
at least 2 hours or for the duration of the procedure (if the 
procedure lasted >2 hours) and was followed by clopido-
grel 600 mg after the infusion of the intravenous study drug. 
Patients randomized to clopidogrel received either 600 or 
300 mg clopidogrel as determined by clinician preference. 
Randomization was stratified by intended loading dose of 
clopidogrel (600 versus 300 mg) and normal or abnormal 
status at baseline (status based on cardiac biomarkers, 
changes in the ECG, and symptoms). Biomarkers of myo-
necrosis (creatinine kinase-MB fraction [CK-MB]; Siemens 
ADVIA Centaur 2-site sandwich immunoassay) were to be 
measured every 6 hours and analyzed by a core laboratory 
(Quest Diagnostics).
end Points
A Clinical Events Committee that was independent, was 
unaware of the treatment assignments, and was based at 
the Duke Clinical Research Institute adjudicated all compo-
nents of the primary and secondary efficacy end points. 
The primary efficacy end point was a composite of death, 
MI, ischemia-driven revascularization, or stent thrombosis 
at 48 hours. The definition of MI used in the adjudication 
of the primary efficacy end point was based on the sec-
ond Universal Definition of MI and was the most contem-
porary definition available at the time in which the trial was 
designed (Table 1).2
To determine whether patients had a periprocedural MI 
within 48 hours of randomization, the Clinical Events Committee 
clinical Perspective
What is new?
•	Cangrelor is an intravenous P2Y12 inhibitor approved 
to reduce periprocedural ischemic events in patients 
undergoing percutaneous coronary intervention not 
previously treated with a P2Y12 inhibitor.
•	4.2% of patients had a myocardial infarction (MI) 
as defined by the second universal definition within 
48 hours after undergoing percutaneous coronary 
intervention.
•	Cangrelor reduced MIs regardless of whether the MI 
was defined with the second universal or Society of 
Coronary Angiography and Intervention definition or 
when MIs were restricted to only those with large 
biomarker elevations and either symptoms or ECG 
changes.
What are the clinical implications?
•	Changes in the definition of MI used in the primary 
end point did not affect the overall findings from the 
CHAMPION PHOENIX trial (Clinical Trial Comparing 
Cangrelor to Clopidogrel Standard of Care Therapy 
in Subjects Who Require Percutaneous Coronary 
Intervention).
•	Some have questioned whether MI remains an 
important clinical event in the current era; however, 
we found that patients who had an MI, regardless 
of the definition, were at increased risk of death at 
30 days.
•	These findings demonstrate the importance of 
therapies that reduce ischemic events in patients 
undergoing percutaneous coronary intervention and 
provide further evidence for the clinical utility of can-
grelor when used in patients undergoing percutane-
ous coronary intervention.
Cangrelor Reduces MI in Patients Undergoing PCI
Circulation. 2016;134:723–733. DOI: 10.1161/CIRCULATIONAHA.115.020829 September 6, 2016
ORIGINAL RESEARCH 
ARTICLE
725
classified patients on the basis of their cardiac biomarker sta-
tus at baseline. Patients were considered to be normal at base-
line if they were undergoing PCI for stable angina, had baseline 
levels of cardiac biomarkers below the 99th percentile, and had 
no new ECG changes or symptoms consistent with acute coro-
nary syndrome within the prior 6 hours. Additionally, patients 
were considered to be normal at baseline if they were classified 
as undergoing PCI for a non–ST-segment–elevation acute coro-
nary syndrome but had 2 biomarker samples ≥6 hours apart 
that were below the 99th percentile, no new ECG changes, 
and no ongoing acute coronary syndrome symptoms or symp-
toms within 6 hours before the sample. In these patients who 
had no evidence of MI at baseline, MI was considered to have 
occurred if there was an elevation in CK-MB that was ≥3 times 
the upper limit of normal (ULN).
All other patients in the trial were considered to be having an 
MI at the time of PCI and were further categorized on the basis 
of whether biomarkers were decreasing and returned to nor-
mal, were decreasing but remaining abnormal, were increas-
ing, or had an unknown baseline. Those patients in whom 
baseline biomarkers were decreasing and were beneath the 
ULN were considered to have a reinfarction if there was an ele-
vation in CK-MB that was ≥3 times the ULN. Patients with bio-
markers that were decreasing at baseline but remained above 
the ULN were considered to have a reinfarction if they had an 
angiographic complication, ischemic symptoms, or new ECG 
table 1. Definitions of Pci-related (type 4a) Mi
end Point 
Definition Baseline Biomarker status
nonbiomarker evidence of 
ischemia
Biomarkers after Pci (core laboratory cK-
MB Mass*)
Definition based on second universal definition
 MI Baseline normal (stable angina, 
non–ST-segment–elevation ACS)
Not required to qualify MI Elevation ≥3× ULN
 Reinfarction Baseline decreasing and returns to 
normal (no intervening event from 
elevated sample to PCI)
Not required to qualify MI Elevation ≥3× ULN
Baseline decreasing and remains 
abnormal (no event from elevated 
sample to PCI)
Need 1 of 3 criteria: angiographic 
complications† OR ischemic 
symptoms‡ OR new ECG changes§
Re-elevation of CKMB ≥3× ULN and ≥50%
Baseline abnormal increasing/
baseline unknown
Angiographic complication† AND new 
ECG changes
Re-elevation of CKMB ≥3× ULN and ≥50%
Definition based on SCAI criteria
 MI Baseline normal (stable angina, 
non–ST-segment–elevation ACS)
None CK-MB to ≥10× ULN
New pathological Q waves in ≥2 
contiguous leads OR LBBB
CK-MB ≥5× ULN
 Reinfarction Baseline falling or stable None New elevation from the prior nadir by an absolute 
increment of ≥10× ULN CK-MB
Baseline rising Angiographic complication† AND new 
ECG changes§
Further increase in cardiac biomarkers (CK-MB 
≥10× ULN) beyond the baseline level
ACS indicates acute coronary syndrome; CK-MB, creatinine kinase-MB; MI, myocardial infarction; PCI, percutaneous coronary intervention; SCAI, 
Society of Coronary Angiography and Intervention; and ULN, upper limit of normal.
*CKMB collection after PCI: 6-hour collection through 24 hours (minimum of 3 samples required). Core laboratory values took priority; hospital laboratory 
values were used if core laboratory values were not available (CK-MB is the priority, but troponin may be used).
†Angiographic evidence of complication (assessed by the angiographic core laboratory): new onset of vessel closure or compromise defined as 
TIMI (Thrombolysis in Myocardial Infarction) grade 0/1 flow after baseline TIMI grade 2/3 flow (also called acute closure or no reflow), TIMI grade 2 
flow after baseline TIMI grade 3 flow (also called slow reflow), sustained distal embolization, or sustained side-branch closure of a vessel ≥2 mm in 
diameter or intraprocedural thrombotic event (IPTE). IPTE is a new or worsening thrombus formation at any time during the procedure. IPTE can be 
a stent-related or non–stent-related complication phenomenon or intraprocedural stent thrombosis (IPST), new or worsening thrombus related to 
the stent, or abrupt closure resulting from thrombosis. Abrupt closure resulting from nonthrombotic causes, including major dissections, perforation, 
or others, were not considered IPST. If a nonthrombotic cause of abrupt stent closure cannot be definitively determined, the cause was considered 
IPST. IPST may present as either acute thrombotic stent closure after a stent was implanted in a patient with a patent vessel beforehand or new 
thrombus formation within or adjacent to a stent in a vessel in which thrombus either was not present or had diminished or resolved before the stent 
was implanted.
‡Ischemic symptoms: angina or equivalent symptoms that needed to be treated medically or lasted ≥20 minutes. Ischemic symptoms as determined 
by the treating physician include but are not limited to weakness, shortness of breath, wheezing, tiredness, fainting, sweating, nausea/vomiting, abdominal 
pain, back pain, jaw pain, palpitations, fast heartbeat, and drug use for chest pain (nitroglycerin, morphine, β-blocker, etc).
§ECG changes: ST-segment elevation or depression >0.1mV (>1 mm) in at least 2 contiguous leads, new LBBB, or new Q wave (>0.03 second).
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changes (new ST-segment elevation/depression >0.1mV in at 
least 2 contiguous leads; new left bundle-branch block; new 
Q wave [> 0.03 seconds]) in conjunction with a re-elevation of 
CK-MB that was ≥3 times the ULN and ≥ 50% higher than the 
nadir. Patients in whom biomarkers were increasing at base-
line (including patients with only 1 elevated biomarker sample 
at baseline or 2 biomarkers values collected <6 hours apart 
that prevented the adequate assessment of the biomarker tra-
jectory) had to have both angiographic evidence consistent 
with a periprocedural event (sustained acute vessel closure, 
new Thrombolysis in Myocardial Infarction grade 0/1 flow, evi-
dence of distal embolization, side-branch closure off a vessel 
≥2 mm in diameter, dissection, thrombus, or no reflow) and 
ischemic ECG changes in addition to a re-elevation of CK-MB 
that was ≥3 times the ULN and ≥50% from baseline. Patients 
determined to have a ST-segment–elevation MI at baseline 
(including those patients with normal baseline cardiac markers 
who are confirmed by the Clinical Events Committee to have a 
baseline ST-segment–elevation MI ECG) were not reviewed for 
potential type 4a MI.
The Society of Coronary Angiography and Intervention 
(SCAI) subsequently proposed a new definition for periproce-
dural MI.5 In this analysis, we retrospectively applied the SCAI 
criteria to those events adjudicated as an MI during the trial. In 
patients with normal cardiac biomarkers at baseline, patients 
had to have an elevation of CK-MB to ≥10 times the ULN. 
Patients who had normal biomarkers at baseline but developed 
new pathological Q waves in ≥2 contiguous leads or left bun-
dle-branch block were considered to have an MI if they have a 
CK-MB elevation ≥5 times the ULN. Patients with cardiac bio-
markers that were either stable or falling at baseline required 
a new elevation from the previous nadir level by an absolute 
increment of ≥10 times the ULN of CK-MB. Patients with bio-
markers that were rising at baseline required a further increase 
in cardiac biomarkers (CK-MB ≥10 times the ULN) beyond the 
last level. In the population of patients with rising biomarkers, 
the SCAI definition also requires signs consistent with a clini-
cally relevant MI (ie, new onset or worsening heart failure or 
sustained hypotension). These specific events were not pro-
spectively collected in the trial. Instead, for this analysis, we 
required patients with biomarkers that were rising at baseline 
to have either new ischemic ECG changes or angiographic evi-
dence consistent with a clinically relevant MI.
The predefined definition of stent thrombosis used in the 
original analysis of CHAMPION PHOENIX included both defi-
nite stent thrombosis (as defined by the Academic Research 
Consortium [ARC]) and IPST (angiographically confirmed new 
or worsening thrombus related to the placement of the coro-
nary stent).6,7 The first sensitivity analysis excluded IPST and 
was the composite of death, MI, ischemia-driven revasculariza-
tion, or ARC definite stent thrombosis at 48 hours after ran-
domization. Additional sensitivity analysis also excluded IPST 
and used revised MI definitions based on SCAI’s proposed 
clinically relevant threshold for an MI (death, MI [SCAI definition 
for peri-procedural events], ischemia-driven revascularization, 
or ARC definite stent thrombosis) and a definition of MI that 
required a postprocedural CK-MB elevation of ≥10 times the 
ULN (death, MI [CK-MB ≥10 times the ULN], ischemia-driven 
revascularization, or ARC definite stent thrombosis) at 48 
hours after randomization.
An academic executive committee and The Medicines 
Company designed the trial. The Medicines Company funded 
the trial. At the conclusion of the trial, the database was trans-
ferred to the Harvard Clinical Research Institute, which had full 
access to the data and validated the analyses included in this 
article. The Institutional Review Board or Ethics Committee for 
each participating institution reviewed and approved the trial. 
All patients provided written informed consent.
statistical analysis
This analysis used the modified intention to treat population of 
patients who underwent PCI and were treated with study drug 
(n=10 942). The association between MI type and the primary 
efficacy end point was examined with a logistic regression 
model that controlled for potential confounders (treatment, 
patient status, age [≥65 years], history of congestive heart 
failure, diabetes mellitus, prior MI, country [United States/
Non–United States], PCI duration).
The effects of cangrelor compared with clopidogrel on MI 
were determined with a logistic regression model that was 
stratified by intended loading dose of clopidogrel (600 versus 
300 mg) and patient status at baseline (normal/abnormal).
A 2-sided significance level of 0.05 was used, and there 
were no corrections for multiple comparisons because of the 
exploratory nature of this analysis. Event curves were devel-
oped from 48-hour Kaplan-Meier estimates. Analyses were 
performed with SAS software version 9.3 (SAS Institute, 
Cary, NC).
resUlts
The primary efficacy end point as originally defined in the 
CHAMPION PHOENIX trial was the composite of death, 
MI, ischemia-driven revascularization, or stent throm-
bosis at 48 hours. In this sensitivity analysis in which 
IPST was not included as part of the stent thrombosis 
events considered in the composite end point, cangrelor 
reduced death, MI, ischemia-driven revascularization, or 
ARC definite stent thrombosis at 48 hours (4.2% versus 
5.2%; odds ratio [OR], 0.80; 95% confidence interval 
[CI], 0.67–0.95; P=0.01; Figure 1). When different defi-
nitions of MI were used in the primary efficacy end point, 
the results of the trial were consistent with previously 
reported results. Treatment with cangrelor reduced the 
composite end point of death, MI (using SCAI definition 
for periprocedural MI), ischemia-driven revascularization, 
or ARC definite stent thrombosis (1.4% versus 2.1%; OR, 
0.69; 95% CI, 0.51–0.92; P=0.01) and the composite 
end point of death, MI (peak CK-MB ≥10 times the ULN), 
ischemia-driven revascularization, or ARC definite stent 
thrombosis (1.4% versus 2.0%; OR, 0.69; 95% CI, 0.51–
0.92; P=0.01; Figure 2).
Treatment with cangrelor reduced the incidence of MI 
at 48 hours (3.8% versus 4.7%; OR, 0.80; 95% con-
fidence interval [CI], 0.67–0.97; P=0.02). Of the 462 
patients with MI that occurred in CHAMPION PHOENIX 
(4.2%), the majority were considered type 4a (related to 
Cangrelor Reduces MI in Patients Undergoing PCI
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PCI; n=433, 93.7%) and occurred in patients with base-
line biomarkers that were normal (Table I in the online-only 
Data Supplement). Treatment with cangrelor reduced the 
incidence of type 4a MI compared with clopidogrel (3.5% 
versus 4.4%; OR, 0.80; 95% CI, 0.66–0.98; P=0.03; Ta-
ble 2). When the SCAI definition of periprocedural MI was 
used for potential ischemic events that occurred during 
the trial, there were fewer overall events (n=134). Treat-
ment with cangrelor also reduced the incidence of MI 
using the SCAI criteria for periprocedural events (1.0% 
versus 1.5%; OR, 0.65; 95% CI, 0.46–0.92; P=0.01). In 
patients with baseline biomarkers that were normal, can-
grelor reduced the incidence of MIs with symptoms and 
CK-MB ≥5 times the ULN (0.4% versus 0.7%; OR, 0.54; 
95% CI, 0.32–0.91; P=0.02). Similarly, cangrelor re-
duced MIs with a peak CK-MB ≥10 times the ULN (0.9% 
versus 1.4%; OR, 0.64; 95% CI, 0.45–0.91; P=0.01) 
and those MI with peak CK-MB ≥10 times the ULN, symp-
toms, or ECG changes (1.5% versus 2.4%; OR, 0.63; 
95% CI, 0.48–0.84; P=0.001). There was no heteroge-
neity in the effects of cangrelor on MI based on index 
diagnosis (Table II in the online-only Data Supplement). 
The distribution of peak biomarkers in patients treated 
with cangrelor and clopidogrel is shown in Figure I in the 
online-only Data Supplement.
Patients randomized in CHAMPION PHOENIX who 
had an MI as defined with the definition in the origi-
nal protocol that was based on the second universal 
definition of MI were at increased risk of death at 30 
days even after adjustment for potential confounders 
(adjusted OR, 4.60; 95% CI, 2.49–8.51; P<0.001; 
Figure 3). MI also was associated with increased risk 
of death at 30 days when using the SCAI definition 
(adjusted OR, 8.85; 95% CI, 4.29–18.25; P<0.001) 
and when considering only MI that resulted in a peak 
CK-MB ≥10 times the ULN (adjusted OR, 9.20; 95% CI, 
4.45–18.99; P<0.001).
DiscUssiOn
In this sensitivity analysis of the CHAMPION PHOENIX 
trial, we found that treatment with cangrelor reduced the 
incidence of death, MI, ischemia-driven revascularization, 
or stent thrombosis regardless of the definition of MI or 
Cangrelor 
N=5472 
n (%)
Clopidogrel 
N=5470 
n (%)
OR (95% CI) p-value 
Protocol Defined Primary Endpoint 
Death/MI/IDR/ST 257/5470 (4.7) 322/5469 (5.9) 0.79 (0.67, 0.93) 0.006 
Sensitivity Analyses
Death, MI, IDR, ARC-ST 230/5470 (4.2) 286/5469 (5.2) 0.80 (0.67, 0.95) 0.01 
Death, MI (SCAI), IDR, ARC ST 79/5470 (1.4) 114/5469 (2.1) 0.69 (0.51, 0.92) 0.01 
Death, MI (CK-MB 10 ULN),  
IDR, ARC-ST 77/5470 (1.4) 111/5469 (2.0) 0.69 (0.51, 0.92) 0.01 
Death, MI (CK-MB 10 ULN MI, 
symptoms, or ECG changes),  
IDR, ARC-ST 
106/5470 (1.9) 161/5469 (2.9) 0.65 (0.51, 0.83) 0.001 
Death, MI (with symptoms or ECG 
changes), IDR, ARC-ST 86/5470 (1.6) 130/5469 (2.4) 0.66 (0.50, 0.86) 0.003 
Death, MI (CK-MB 10 ULN MI in pts 
with normal baseline biomarkers), 
IDR, ARC-ST 
75/5470 (1.4) 108/5469 (2.0) 0.69 (0.51, 0.93) 0.01 
Death/MI (Q Wave)/IDR/ARC-ST 49/5470 (0.9) 64/5469 (1.2) 0.76 (0.53, 1.11) 0.16 
Favors Cangrelor Favors Clopidogrel 
0.1 1 10 
Figure 1. Protocol-defined and sensitivity analyses of primary efficacy end points at 48 hours using different 
definitions of myocardial infarction (Mi). 
ARC indicates Academic Research Consortium; CI, confidence interval; CK-MB, creatinine kinase-MB; IDR, ischemia-driven 
revascularization; OR, odds ratio; SCAI, Society of Coronary Angiography and Intervention; ST, stent thrombosis; and ULN, 
upper limit of normal.
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stent thrombosis. The consistency of the results across 
a variety of different definitions supports the efficacy 
of cangrelor in patients undergoing PCI. Furthermore, 
cangrelor reduced MIs of different sizes, but particularly 
those MIs associated with high levels of biomarkers and 
MIs that were associated with signs or symptoms of 
ischemia. We also found that the occurrence of an MI, 
regardless of type, remains associated with significant 
odds of death in the 30 days after the event. Thus, the 
benefits of cangrelor in reducing periprocedural MI re-
main clinically important in the current era.
Because the majority of ischemic events that occurred 
during the first 48 hours of CHAMPION PHOENIX were 
type 4a MIs related to PCI, these data highlight the need 
for adequate and effective antithrombotic therapies.8 
Current guidelines recommend that patients undergoing 
Figure 2. sensitivity analyses evaluating outcomes at 48 hours of cangrelor compared with clopidogrel using 
different definitions of myocardial infarction (Mi). 
Time to first occurrence of (A) death, MI (Society of Coronary Angiography and Intervention [SCAI] definition), ischemia-driven 
revascularization (IDR), and Academic Research Consortium (ARC) definite stent thrombosis (ST) and (B) death, MI (creatinine 
kinase-MG [CK-MB] ≥10 times the upper limit of normal [ULN]), IDR, and ARC definite stent thrombosis. OR indicates odds ratio.
Cangrelor Reduces MI in Patients Undergoing PCI
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PCI be treated with oral antiplatelet therapies before or 
immediately after the procedure.9–11 The oral P2Y12 in-
hibitors currently used in practice have a delayed onset 
of action and do not result in antiplatelet effects for ≈60 
to 120 minutes.12,13 The delay in the onset of antiplatelet 
effect is a particular problem in patients such as those 
treated with ad hoc PCI after elective coronary angiogra-
phy or in patients undergoing PCI for acute coronary syn-
drome in whom little antiplatelet effect may be present 
during the actual PCI. Furthermore, some medications 
such as those used during moderate sedation may delay 
the onset of antiplatelet effects.14
Intravenous glycoprotein IIb/IIIa inhibitors are avail-
able and can be used in patients undergoing PCI who are 
not pretreated with an oral P2Y12 inhibitor.
15 However, 
prior studies showed that the majority of benefit from 
glycoprotein IIb/IIIa inhibitors occurred in patients with 
elevated cardiac biomarkers, yet the EARLY-ACS trial 
(Early Glycoprotein IIb/IIIa Inhibition in Non–ST-Segment 
Elevation Acute Coronary Syndrome) and ACUITY trial 
(Acute Catheterization and Urgent Intervention Triage 
Strategy) showed that the routine use of these agents 
in these populations increased the risk of bleeding with-
out significant improvements in clinical outcomes.16,17 
As a result, the use of glycoprotein IIb/IIIa inhibitors has 
declined, and some current guidelines do not endorse 
routine use.9 Because cangrelor is an intravenous formu-
lation that has high bioavailability and is a highly effective 
platelet inhibitor, it is likely that much of the benefit with 
regard to the reduction of MI seen in this study reflects an 
antiplatelet effect that is more potent and occurs more 
quickly than the effects of clopidogrel.18 Prior studies 
have shown that more intensive antiplatelet therapy can 
reduce ischemic events in patients undergoing PCI.10,11,19 
These findings from CHAMPION PHOENIX build on prior 
studies and show that drugs with greater bioavailability 
and a faster onset of action can reduce ischemic events 
even compared with effective antiplatelet therapies.20–23
Some have questioned whether MIs, particularly 
those events with low elevations in cardiac biomarkers 
that may not have been previously detected, are clini-
cally relevant in the contemporary era.24,25 We found 
that patients with an MI after randomization had a risk of 
death that was between 4- and 13-fold greater than that 
table 2. effect of cangrelor on Mi at 48 hours
cangrelor (n=5472) clopidogrel (n=5470) Or (95% ci) P Value
MI (universal definition) 207/5470 (3.8) 255/5469 (4.7) 0.80 (0.67–0.97) 0.02
 Type 1 1/5470 (0.0) 1/5469 (0.0) 1.00 (0.06–15.99) >0.99
 Type 2 0/5470 (0.0) 0/5469 (0.0) … …
 Type 3 3/5470 (0.1) 0/5469 (0.0) … …
 Type 4a 194/5470 (3.5) 239/5469 (4.4) 0.80 (0.66–0.98) 0.03
 Type 4b 9/5470 (0.2) 15/5469 (0.3) 0.60 (0.26–1.37) 0.22
 Type 5 0/5470 (0.0) 0/5469 (0.0) … …
MI (SCAI definition)* 53/5470 (1.0) 81/5469 (1.5) 0.65 (0.46–0.92) 0.01
MI (by peak CK-MB)
 Peak 3–<5× ULN 101/5470 (1.8) 126/5469 (2.3) 0.80 (0.61–1.04) 0.09
 Peak 5–<10× ULN 82/5470 (1.5) 83/5469(1.5) 0.99 (0.73–1.34) 0.94
 Peak ≥10× ULN 50/5470 (0.9) 78/5469 (1.4) 0.64 (0.45–0.91) 0.01
Q wave 11/5470 (0.2) 18/5469 (0.3) 0.61 (0.29–1.29) 0.19
Non–Q wave 196/5470 (3.6) 237/5469 (4.3) 0.82 (0.68–1.00) 0.04
STEMI 24/5470 (0.4) 34/5469 (0.6) 0.70 (0.42–1.19) 0.19
Non-STEMI 183/5470 (3.3) 221/5469 (4.0) 0.82 (0.67–1.00) 0.05
MI with symptoms or ECG changes 62/5470 (1.1) 99/ 5469 (1.8) 0.62 (0.45–0.86) 0.004
MI with peak CK-MB ≥10× ULN, 
symptoms, or ECG changes
83/ 5470 (1.5) 130/5469 (2.4) 0.63 (0.48–0.84) 0.001
MI with peak CK-MB ≥10× ULN in 
patients with normal baseline biomarker
38/ 3519 (1.1) 64/ 3431 (1.9) 0.57 (0.38, 0.86) 0.01
CI indicates confidence interval; CK-MB, creatinine kinase-MB; MI, myocardial infarction; OR, odds ratio; SCAI, Society of Coronary Angiography and 
Intervention; STEMI, ST-segment–elevation myocardial infarction; and ULN, upper limit of normal.
* Protocol definition of MI used but replaces type 4a MI with peri–percutaneous coronary intervention MI as defined with the definition based on the 
SCAI criteria.
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for patients who had no event. The clear association be-
tween MI and death, which was present for all definitions 
of MI evaluated in these analyses, provides evidence that 
therapies designed to reduce MIs are likely important in 
the treatment of patients undergoing PCI.
Numerous definitions of MI have been proposed for 
use in clinical trials2,5,26; however, the optimal definition 
remains unclear.7,27 Furthermore, differences in the defini-
tions change the incidence of periprocedural MI as noted 
by the fact that only 31% of the type 4a MIs as defined 
by the second universal definition met the SCAI criteria. 
The second universal definition of MI noted that it was 
difficult to define MI in patients with elevated biomarkers 
at baseline. These guidelines suggested including crite-
ria that incorporate features supportive of ischemia (eg, 
imaging, ECG). In CHAMPION PHOENIX, patients with ele-
vated biomarkers required evidence of symptoms, angio-
graphic evidence consistent with a periprocedural event, 
or ischemic ECG changes, in addition to further elevations 
in biomarkers, to be considered as having a type 4a MI. 
In patients who had no evidence of MI at baseline, MI was 
considered to have occurred if there was an elevation in 
CK-MB that was ≥3 times the ULN regardless of whether 
symptoms were present. The third universal definition now 
requires that patients have signs or symptoms of myocar-
dial ischemia regardless of baseline biomarkers. In addi-
tion, the third universal definition proposes a >5-fold rise 
above the 99th percentile for the upper reference limit for 
patients with normal biomarkers at baseline to meet the 
MI definition.26
The SCAI definition differs in some important ways 
from the universal definition. Patients with normal car-
diac biomarkers at baseline had to have an elevation of 
CK-MB to ≥10 times the ULN or cardiac troponin (I or 
T) to ≥70 times the ULN to meet the definition of MI. 
Although this definition identified fewer events in CHAM-
PION PHOENIX, the events identified were clinically 
meaningful and were associated with increased risk of 
death at 30 days even when controlling for the extent of 
coronary artery disease.
These data should be considered in light of some limi-
tations. First, these analyses are post hoc analyses that 
were not prespecified. As a result, they represent sen-
sitivity analyses that supplement the findings from the 
predefined, primary results of the trial. Accordingly, the 
MI definition based on the SCAI criteria was not prospec-
tively adjudicated and was obtained retrospectively. This 
trial assessed MI using the universal definition that was 
available at that time the trial was designed and did not 
use the third universal definition that is now available. 
In addition, CK-MB was systematically collected in the 
CHAMPION PHOENIX trial, whereas the second and third 
universal definitions of MI prefer cardiac troponin. Bleed-
ing was investigator reported and was not adjudicated, 
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although post hoc adjudication did not qualitatively 
change the safety profile.23 Finally, CHAMPION PHOENIX 
was not powered for this specific component of the pri-
mary end point or to assess the effects of cangrelor on 
specific types of MI.
cOnclUsiOns
MI, as defined with a variety of different classifications, 
continues to be an important event in the contemporary 
era that significantly increases the risk of death at 30 
days. Although there are multiple proposed definitions 
of MI and these different definitions result in changes 
in the incidence of MI, there were no qualitative differ-
ences in the effects of cangrelor with the use of vari-
ous definitions. As a result, cangrelor was effective in 
reducing ischemic events in patients undergoing PCI in 
CHAMPION PHOENIX regardless of the definition of MI 
tested in this study.
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